Results 21 to 30 of about 46,511 (209)
The Rationale for Potential Pharmacotherapy of COVID-19
Pharmaceuticals, 2020 On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first ...
Maha Saber-Ayad +2 more
doaj +1 more source
Personalizing HIV therapy, mission impossible? [PDF]
, 2012 Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core +1 more source
Changes in insulin sensitivity over time and associated factors in HIV-infected adolescents [PDF]
, 2018 OBJECTIVE: To compare prevalence of insulin resistance between perinatally HIV-infected (PHIV+) and perinatally HIV-exposed, but uninfected adolescents (PHEU), determine incidence of and contributory factors to new and resolved cases of insulin ...
Dimeglio, Linda A. +13 more
core +2 more sources
Chemical and Toxicological Analysis of Antiretroviral Drugs
Разработка и регистрация лекарственных средств, 2019 Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov +7 more
doaj +1 more source
A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]
, 2019 Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y. +2 more
core +1 more source
Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19
Реальная клиническая практика: данные и доказательства, 2022 According to a number of studies, medicinal plants and drugs based on them can be used as inhibitors of various viral infections, including the SARS-CoV-2 virus at different stages of their manifestation and development.
A. A. Taube
doaj +1 more source
Use of B‐complex vitamins and olfactory training for treating COVID‐19–related anosmia
Clinical Case Reports, 2021 A 42‐year‐old male patient was diagnosed with coronavirus disease 2019. His symptoms improved 2 weeks after lopinavir therapy (800 mg/day). However, he was subsequently diagnosed with complete anosmia.
Yethindra Vityala +4 more
doaj +1 more source
AIDS Research and Therapy, 2012 Background Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes dyslipidaemia.
Sinxadi Phumla Z +5 more
doaj +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Journal of Infection and Public Health, 2021 Background: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been ...
Tejas K. Patel +5 more
doaj +1 more source